Vivet Therapeutics
Vivet Therapeutics - innovative gene therapy treatments for orphan diseasesVivet TherapeuticsVivet Therapeutics

innovative gene therapy treatments for orphan diseases

  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Category Archives: News

Vivet Therapeutics   →  News
28
Oct
Date 28 October 2021
Categories News

Vivet Therapeutics awarded with the Prix Galien MedStartup in New York

Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing Or Underserved Populations Worldwide”.
Read More
Author admin_viv3t
07
Sep
Date 7 September 2021
Categories News

GATEWAY clinical trial for Wilson Disease has now its website

Wilson Disease is a rare, progressive genetic disorder that causes excess copper to be stored in the body.
Read More
Author admin_viv3t
12
Aug
Date 12 August 2021
Categories News

VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Read More
Author admin_viv3t
08
Jul
Date 8 July 2021
Categories News

Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease

Learn how  gene therapy aims to target the cause of  Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.
Read More
Author admin_viv3t
22
Jun
Date 22 June 2021
Categories News

Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!

Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Read More
Author admin_viv3t
12
Apr
Date 12 April 2021
Categories News

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s PFIC Gene Therapy Programs

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Read More
Author admin_viv3t
18
Nov
Date 18 November 2020
Categories News

Vivet and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for WD

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
Read More
Author admin_viv3t
23
Sep
Date 23 September 2020
Categories News

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Read More
Author admin_viv3t
15
Sep
Date 15 September 2020
Categories News

Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020

Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.
Read More
Author admin_viv3t
01
Jun
Date 1 June 2020
Categories News

Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.

PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Read More
Author admin_viv3t
1 2 Next page

Last news

  • Vivet Therapeutics awarded with the Prix Galien MedStartup in New York28 October 2021
  • GATEWAY clinical trial for Wilson Disease has now its website7 September 2021
  • VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease12 August 2021
  • Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease8 July 2021
  • Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!22 June 2021
All NEWS

Last events

  • Vivet presenting during the 6th annual Gene Therapy for Rare Disorders in Boston20 March 2023
  • Vivet presenting at the EPA World Congress in Amsterdam20 March 2023
  • Vivet attending World Orphan Drug Congress 2022 in Sitjes14 November 2022
  • Vivet attending Spanish Wilson disease patients association annual conference in Valencia, Spain – Nov. 12-13 202212 November 2022
  • Vivet presenting new Real World data on Wilson disease during ISPOR EU 2022 in Vienna, Austria – Nov. 6-9 20226 November 2022
  • Vivet presenting at 6th annual Gene Therapy for Rare Disorders Europe in London26 October 2022
All EVENTS

About us

  • Our DNA
  • Board members
  • Our leadership
  • Partners

Pipeline

  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1

Patients & Families

  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact